We currently do not have sufficient information about the CEO.
Key information
Constantine Nkafu
Chief executive officer
US$122.5k
Total compensation
CEO salary percentage
100.00%
CEO tenure
1.2yrs
CEO ownership
n/a
Management average tenure
no data
Board average tenure
2yrs
Recent management updates
Recent updates
CEO Compensation Analysis
How has Constantine Nkafu's remuneration changed compared to CannaPharmaRX's earnings?
Date
Total Compensation
Salary
Company Earnings
Dec 31 2025
US$122k
US$122k
-US$11m
Sep 30 2025
n/a
n/a
-US$7m
Jun 30 2025
n/a
n/a
-US$6m
Mar 31 2025
n/a
n/a
US$1m
Dec 31 2024
US$93k
US$29k
-US$10m
Compensation vs Market: Constantine's total compensation ($USD122.46K) is below average for companies of similar size in the US market ($USD647.55K).
Compensation vs Earnings: Constantine's compensation has increased whilst the company is unprofitable.
CEO
Constantine Nkafu (49 yo)
1.2yrs
Tenure
US$122,464
Compensation
Mr. Constantine Nkafu is Director of CannaPharmaRX, Inc. from March 2025 and is also its Chief Executive Officer and served as its Interim CEO. Mr. Nkafu has extensive experience in the Pharmaceutical, Can...
Board Members
Name
Position
Tenure
Compensation
Ownership
Constantine Nkafu
CEO & Director
1.2yrs
US$122.46k
no data
Dominick Colvin
Director
7.3yrs
US$148.77k
0.15% $ 3.0k
Anthony Panek
Director
2.8yrs
no data
no data
Elliot Zemel
Director
1.2yrs
no data
no data
2.0yrs
Average Tenure
44.5yo
Average Age
Experienced Board: CPMD's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/18 14:49
End of Day Share Price
2026/05/15 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CannaPharmaRX, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.